NewAmsterdam Pharma Balance Sheet Health
Financial Health criteria checks 6/6
NewAmsterdam Pharma has a total shareholder equity of $387.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $446.7M and $59.3M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$430.71m |
| Equity | US$387.44m |
| Total liabilities | US$59.25m |
| Total assets | US$446.69m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: NAMS's short term assets ($445.4M) exceed its short term liabilities ($45.3M).
Long Term Liabilities: NAMS's short term assets ($445.4M) exceed its long term liabilities ($13.9M).
Debt to Equity History and Analysis
Debt Level: NAMS is debt free.
Reducing Debt: NAMS had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NAMS has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: NAMS has sufficient cash runway for 2.5 years if free cash flow continues to reduce at historical rates of 71.3% each year.